Dupilumab for cancer-associated refractory pruritus

Dupilumab for cancer-associated refractory pruritus

Background: Pruritus can be an intolerable symptom in patients with cancer. Type 2 inflammation, and specifically, the cytokines IL-4, IL-13, and IL-31, play major roles in the itching process. Dupilumab is an antibody against IL-4Rα, which is a common IL-4 and IL-13 receptor subunit. Blocking IL-4...

תיאור מלא

מידע ביבליוגרפי
Main Authors: Aviv Talmon, MD, Shlomo Elias, MD, PhD, Limor Rubin, MD, Yaarit Ribak, MD, Eyal Ben Dori, MD, Oded Shamriz, MD, Michal Lotem, MD, Irit Adini, PhD, Yuval Tal, MD, PhD
פורמט: Article
שפה:English
יצא לאור: Elsevier 2023-08-01
סדרה:Journal of Allergy and Clinical Immunology: Global
נושאים:
Oncologic pruritus
chronic pruritus
itch
IL-4
IL-13
IL-31
גישה מקוונת:http://www.sciencedirect.com/science/article/pii/S277282932300053X

אינטרנט

http://www.sciencedirect.com/science/article/pii/S277282932300053X

פריטים דומים